Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Troponin Assays Receive US Marketing Clearance

By LabMedica International staff writers
Posted on 08 Aug 2018
Two high precision assays for the measurement of the cardiac marker troponin I (TnIH) have been certified for marketing in the United States.

The detection of a rise and/or fall of cardiac troponin (cTn) plays a key role in the early diagnosis of myocardial infarction (MI). More...
Cardiac troponins are markers of myocardial necrosis, and, because of their high cardiac-specificity, are the preferred biomarker for the diagnosis of MI.

Troponin is a complex of three contractile regulatory proteins, troponin C, T, and I that control the calcium mediated interactions between actin and myosin in cardiac and skeletal muscles. Troponin I and T are specific to cardiac muscles, unlike troponin C which is associated with both cardiac and skeletal muscles. Both troponin I and troponin T are released into circulation at the time of injury following the same release pattern in the system. However, cardiac troponin I is slightly more differentiated from skeletal troponin I than cardiac troponin T is from skeletal troponin T.

Siemens Healthineers (Erlangen, Germany) has announced that two of its high precision troponin assays have been cleared by the [U.S.] Food and Drug Administration. The High-Sensitivity Troponin I assays (TnIH) for Siemens' Atellica (immunoassay and clinical chemistry analyzer) and ADVIA Centaur XP/XPT (immunoassay system) instruments are now available in the United States.

The high-sensitivity performance of the two new TnIH assays enables detection of lower levels of troponin at significantly improved precision at the 99th percentile, and detects smaller changes in a patient’s troponin level during repeated testing.

The High-Sensitivity Troponin I assays from Siemens Healthineers will be highlighted during the 70th AACC Annual Scientific Meeting & Clinical Lab Expo taking place from July 31 to August 2, 2018, in Chicago, IL, USA.

“Our emergency department is overcrowded with patients. If we can do a more efficient job at triaging patients to receive the proper level of care and to discharge the patients who do not need to stay in the emergency department, this will have a tremendous economic advantage for our healthcare system,” said Dr. Alan Wu, chief of clinical chemistry and toxicology at Zuckerberg San Francisco General Hospital and Trauma Center.


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.